ProductUpdated on 30 December 2025
MID Prism (AI-Powered Diagnostics)
CEO & Founder at M Bio Technology Inc.
TOKYO, Japan
About
• Detects antibody levels even in asymptomatic patients
• Monitors disease from acute to chronic stages
-
Clinical Lead Partners: European University Hospitals
-
Public Health & Epidemiological Partners: Institutions
-
Regulatory & Market Access Experts: Partners familiar with EU MDR and the AI Act to navigate the fast-track approval process for MID Prism and MID Modality in Europe.
-
Horizon Europe Consortium Coordinators: Established EU entities looking for a high-tech Japanese SME to join proposals under Cluster 4 (Digital/Industry) or Cluster 1 (Health).
Organisation
Similar opportunities
Project cooperation
Kazuhiro Matsuda
CEO & Founder at M Bio Technology Inc.
TOKYO, Japan
Product
MID Modality (Vaccine Innovation)
Kazuhiro Matsuda
CEO & Founder at M Bio Technology Inc.
TOKYO, Japan